Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: Naphthalene, styrene, and toluene

Chemical Research in Toxicology

Volumn 21, Issue 3, 2008, Pages 720-725

  Fukami, Tatsuki ^a   Katoh, Miki ^a   Yamazaki, Hiroshi ^a,b   Yokoi, Tsuyoshi ^a   Nakajima, Miki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Showa Pharmaceutical University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHOL; 4 NITROPHENOL; 6 HYDROXYCHLORZOXAZONE; BENZYL ALCOHOL; CYTOCHROME P450 1A2; CYTOCHROME P450 2A; CYTOCHROME P450 2A13; CYTOCHROME P450 2E1; NAPHTHALENE; NAPHTHOQUINONE; STYRENE; TOBACCO SMOKE; TOLUENE; UNCLASSIFIED DRUG;

AIR POLLUTANT; ARTICLE; CARCINOGENICITY; CATALYSIS; CONTROLLED STUDY; EPOXIDATION; HYDROXYLATION; NONHUMAN; TOXICOKINETICS;

AIR POLLUTANTS; CATALYSIS; CYTOCHROME P-450 CYP3A; ESCHERICHIA COLI; HYDROXYLATION; KINETICS; MEMBRANE PROTEINS; NAPHTHALENES; NAPHTHOLS; STYRENES; TOLUENE;

NICOTIANA TABACUM;

EID: 41849093006     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx700325f     Document Type: Article

References (47)

1. Fernandez-Salguero, P., Hoffman, S. M. G., Cholerton, S., Mohrenweiser, H., Raunio, H., Rautio, A., Pelkonen, O., Huang, J., Evans, W. E., Idle, J. R., and Gonzalez, F. J. (1995) A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57, 651-660.
2. Yamano, S., Tatsuno, J., and Gonzalez, F. J. (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29, 1322-1329.
3. Su, T., Bao, Z., Zhang, Q. Y., Smith, T. J., Hong, J. Y., and Ding, X. (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 60, 5074-5079.
4. Bao, Z., He, X. Y., Ding, X., Prabhu, S., and Hong, J. Y. (2005) Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab. Dispos. 33, 258-261.
5. Koskela, S., Hakkola, J., Hukkanen, J., Pelkonen, O., Sorri, M., Saranen, A., Anttila, S., Fernandez-Salguero, P., Gonzalez, F., and Raunio, H. (1999) Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 57, 1407-1413.
6. Gu, J., Su, Y., Chen, Q. Y., Zhang, X., and Ding, X. (2000) Expression and biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol. Appl. Pharmacol. 165, 158-162.
7. 1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int. J. Cancer 118, 2665-2671.
8. Fukami, T., Nakajima, M., Sakai, H., Katoh, M., and Yokoi, T. (2007) CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin and theophylline. Drug Metab. Dispos. 35, 335-339.
9. Nakajima, M., Ito, M., Sakai, H., Fukami, T., Katoh, M., Yamazaki, H., Kadlubar, F. F., Imaoka, S., Funae, Y., and Yokoi, T. (2006) CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int. J. Cancer 119, 2520-2526.
10. Kulisch, G. P., and Vilker, V. L. (1991) Application of Pseudomonas pulid PpG786 containing P-450 cytochrome monooxygenase for removal of trace naphthalene concentrations. Biotechnol. Prog. 7, 93-98.
11. Stucker, I., Bouyer, J., Mandereau, L., and Hemon, D. (1993) Retrospective evaluation of the exposure to polycyclic aromatic hydrocarbons: comparative evaluations with a job exposure matrix and by experts in industrial hygiene. Int. J. Epidemiol. 22, 5106-5112.
12. Vuchetich, P. J., Bagchi, D., Bagchi, M., Hassoun, E. A., Tang, L., and Stohs, S. J. (1996) Naphthalene-induced oxidative stress in rats and the prospective effects of vitamine E succinate. Free Radical Biol. Med. 21, 577-590.
13. Wilson, A. S., Davis, C. D., Williams, D. P., Buckpitt, A. R., Pirmohamed, M., and Park, B. K. (1996) Characterisation of the toxic metabolite. (s) of naphthalene. Toxicology 114, 233-242.
14. Cho, T. M., Rose, R. L., and Hodgson, E. (2006) In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug. Metab. Dispos. 34, 176-183.
15. Kanekal, S., Plopper, C., Morin, D., and Buckpitt, A. (1991) Metabolism and cytotoxicity of naphthalene oxide in the isolated perfused mouse lung. J. Pharmacol. Exp. Ther. 256, 391-401.
16. Buckpitt, A., Chang, A. M., Weir, A., Van Winkle, L., Duan, X., Philpot, R., and Plopper, C. (1995) Relationship of cytochrome P450 activity to Clara cell cytotoxicity. IV. Metabolism of naphthalene and naphthalene oxide in microdissected airways from mice, rats and hamsters. Mol. Pharmacol. 47, 74-81.
17. IARC (1989) Toluene. IARC Monograph on Evaluation of the Carcinogenic Risks of Chemicals to Humans 47, 79-123, IARC, Vienna, Austria.
18. IARC (1994) Styrene. IARC Monograph on Evaluation of the Carcinogenic Risks of Chemicals to Humans 60, 233-320, IARC, Vienna, Austria.
19. Bond, J. A. (1989) Review of the toxicology of styrene. CRC Crit. Rev. Toxicol. 19, 227-249.
20. Foo, S. C., Jeyaratnam, J., and Koh, D. (1990) Chronic neurobehavioral effects of toluene. Br. J. Ind. Med. 47, 480-484.
21. Nakajima, T., Elovaara, E., Gonzalez, F. J., Gelboin, H. V., Raunio, H., Pelkonen, O., Vainio, H., and Aoyama, T. (1994) Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem. Res. Toxicol. 7, 891-896.
22. Tassaneeyakul, W., Birkett, D. J., Edwards, J. W., Veronese, M. E., Tassaneeyakul, W., Tukey, R. H., and Miners, J. O. (1996) Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene. J. Pharmacol. Exp. Ther. 276, 101-108.
23. Nakajima, T., Wang, R-S., Elovaara, E., Gonzalez, F. J., Gelboin, H. V., Raunio, H., Pelkonen, O., Vainio, H., and Aoyama, T. (1997) Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem. Pharmacol. 53, 271-277.
24. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression Purif. 24, 329-337.
25. Fukami, T., Nakajima, M., Yoshida, R., Tsuchiya, Y., Fujiki, Y., Katoh, M., McLeod, H. L., and Yokoi, T. (2004) A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin. Pharmacol. Ther. 76, 519-527.
26. Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., Takamiya, M., Aoki, Y., and Yokoi, T. (2005) CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos. 33, 1811-1818.
27. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239, 2370-2378.
28. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
29. Williams, C. H., Jr., and Kamin, H. (1962) Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J. Biol. Chem. 237, 587-595.
30. Yasukochi, Y., and Masters, B. S. (1995) Some properties of detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinities chromatography. J. Biol. Chem. 251, 5337-5344.
31. Parikh, A., Gillam, E. M., and Guengerich, F. P. (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotechnol. 15, 784-788.
32. Court, M. H., Von Moltke, L. L., Shader, R. I., and Greenblatt, D. J. (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm. Drug Dispos. 18, 213-226.
33. Jiang, Y., Kuo, C. L., Pernecky, S. J., and Piper, W. N. (1998) The detection of cytochrome P450 2E1 and its catalytic activity in rat testis. Biochem. Biophys. Res. Commun. 246, 578-583.
34. Asikainen, A., Tarhanen, J., Poso, A., Pasanen, M., Alhava, E., and Juvonen, R. O. (2003) Predictive value of comparative molecular field analysis modeling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol. in Vitro 17, 449-455.
35. Shield, A. J., and Sanderson, B. J. (2004) A recombinant model for assessing the role of GSTM1 in styrene-7,8-oxide toxicity and mutagenecity. Toxicology 195, 61-68.
36. Laffon, B., Perez-cadahia, B., Pasaro, E., and Mendez, J. (2003) Individual sensitivity to DNA damage induced by styrene in vitro: influence of cytochrome P450 epoxide hydrolase and glutathione S-transferase genotypes. Toxicology 186, 131-141.
37. Guengerich, F. P., Kim, D. H., and Iwasaki, M. (1991) Role of human cytochrome P450 2E1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179.
38. Smith, B. D., Sanders, J. L., Porubsky, P. R., Lushington, G. H., Stout, C. D., and Scott, E. E. (2007) Structure of the human lung cytochrome P450 2A13. J. Biol. Chem. 282, 17306-17313.
39. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem. 282, 14348-14355.
40. Zhu, L. R., Thomas, P. E., Lu, G., Reuhl, K. R., Yang, G. Y., Wang, L. D., Wang, S. L., Yang, C. S., He, X. Y., and Hong, J. Y. (2006) CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab. Dispos. 34, 1672-1676.
41. Shimada, T., Yamazaki, H., Mimura, M., Wakamiya, N., Ueng, Y.-F., Guengerich, F. P., and Inui, Y. (1996) Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metab. Dispos. 24, 515-522.
42. Zhang, X., Su, T., Zhang, Q. Y., Gu, J., Caggana, M., Li, H., and Ding, X. (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J. Pharmacol. Exp. Ther. 302, 416-423.
43. Fujieda, M., Yamazaki, H., Kiyotani, K., Muroi, A., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y., and Kamataki, T. (2003) Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. Drug Metab. Pharmacokinet. 18, 86-90.
44. Wang, S. L., He, X. Y., Shen, J., Wang, J. S., and Hong, J. Y. (2006) The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant. Toxicol. Sci. 94, 38-45.
45. Zhang, X., Caggana, M., Cutler, T. L., and Ding, X. (2004) Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung. J. Pharmacol. Exp. Ther. 311, 373-381.
46. Wang, H., Tan, W., Hao, B., Miao, X., Zhou, G., He, F., and Lin, D. (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most activate cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. 63, 8057-8061.
47. Cauffiez, C., Lo-Guidice, J.-M., Quaranta, S., Allorge, D., Chevalier, D., Cenee, S., Hamdan, R., Lhermitte, M., Lafitte, J.-J., Libersa, C., Colombel, J.-F., Stücker, I., and Broly, F. (2004) Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem. Biophys. Res. Commun. 317, 662-669.